Enhances various R packages that support the design and simulation of phase 1 dose-escalation trials, adding diagnostics to examine the safety characteristics of these designs in light of expected inter-individual variation in pharmacokinetics and pharmacodynamics.
Norris DC. Dose Titration Algorithm Tuning (DTAT) should supersede ‘the’ Maximum Tolerated Dose (MTD) in oncology dose-finding trials. F1000Research. 2017;6:112. 10.12688/f1000research.10624.3. https://f1000research.com/articles/6-112/v3
Norris DC. Costing ‘the’ MTD. bioRxiv. August 2017:150821. 10.1101/150821. http://www.biorxiv.org/content/early/2017/08/22/150821
Norris DC. Precautionary Coherence Unravels Dose Escalation Designs. bioRxiv. December 2017:240846. 10.1101/240846. https://www.biorxiv.org/content/early/2017/12/29/240846
Norris DC. One-size-fits-all dosing in oncology wastes money, innovation and lives. Drug Discov Today. 2018;23(1):4-6. 10.1016/j.drudis.2017.11.008. https://www.sciencedirect.com/science/article/pii/S1359644617303586
Norris DC. Costing ‘the’ MTD ... in 2-D. bioRxiv. July 2018:370817. 10.1101/370817. https://www.biorxiv.org/content/early/2018/07/17/370817
Norris DC. Ethical Review and Methodologic Innovation in Phase 1 Cancer Trials. JAMA Pediatrics. 2019;173(6):609 10.1001/jamapediatrics.2019.0811.
Norris DC. Comment on Wages et al., Coherence principles in interval-based dose finding. Pharmaceutical Statistics 2019, DOI: 10.1002/pst.1974. Pharmaceutical Statistics. March 2020. 10.1002/pst.2016.
Norris DC. Retrospective analysis of a fatal dose-finding trial. arXiv:2004.12755 [stat, q-bio]. April 2020. http://arxiv.org/abs/2004.12755